Novocure (NASDAQ: NVCR) has announced the appointment of Frank Leonard as the new Chief Executive Officer, effective immediately. Leonard, who previously served as the President of Novocure, is taking over from former CEO Ashley Cordova, who resigned from the company. During his more than 15-year career at Novocure, Leonard has been instrumental in leading global business operations and has played a key role in preparing the company for its first commercial launch.
Leonard's appointment comes at a crucial time for Novocure, as the company looks forward to transformative milestones in the years ahead. His deep expertise in delivering the company's unique, device-based cancer therapy to patients and his unwavering commitment to Novocure's patient-forward mission make him the ideal candidate to lead the organization.
Under Leonard's leadership, Novocure has made significant strides in its global operations. He has been involved in establishing the company's finance, reimbursement, and business development functions, as well as leading the early innovation and product development teams. As President, Leonard led various critical functions including global sales, marketing, field medical affairs, patient experience, public affairs, market access, and product and portfolio strategy.
Novocure, a global oncology company, is focused on extending survival in aggressive forms of cancer through the development and commercialization of its innovative therapy, tumor treating fields. The company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and pleural mesothelioma. Novocure also has several ongoing or completed clinical trials exploring the use of tumor treating fields therapy in the treatment of glioblastoma, non-small cell lung cancer, and pancreatic cancer.
The company's global headquarters is located in Baar, Switzerland, with U.S. headquarters in Portsmouth, New Hampshire, and research and development facilities in Haifa, Israel.
Leonard's appointment as CEO marks a significant transition for Novocure, and his leadership will be critical as the company prepares to launch products in new indications, complete multiple clinical trials, and work towards delivering the full potential of its innovative therapy. As a result of these announcements, the company's shares have moved 0.39% on the market, and are now trading at a price of $12.81. If you want to know more, read the company's complete 8-K report here.
